Myelodysplastic Syndrome and Minimal Change Nephrotic Syndrome treated with Steroid Challenge.
- Author:
Sang Ah LEE
1
;
Jang Hwan LIM
;
Ji Hun JANG
;
Soon Hee CHANG
;
Eun Kyoung KWAK
;
Duk Hyun LEE
;
Sun Ah LEE
Author Information
- Publication Type:Case Report
- Keywords: Myelodysplastic syndromes; Nephrotic syndrome; Steroids
- MeSH: Anemia, Refractory; Cell Differentiation; Glomerulonephritis; Hematopoietic Stem Cells; Humans; Myelodysplastic Syndromes*; Nephrosis, Lipoid*; Nephrotic Syndrome; Pancytopenia; Prednisolone; Proteinuria; Steroids
- From:Korean Journal of Medicine 2016;90(1):63-67
- CountryRepublic of Korea
- Language:Korean
- Abstract: Glomerulonephritis associated with malignancy is deemed to be paraneoplastic glomerulonephritis. Myelodysplastic syndrome (MDS) is a group of heterogeneous clonal hematopoietic stem cell disorders characterized by impaired hematopoietic cell differentiation and cytopenia. The pathophysiology of MDS is thought to be immune-mediated in part. A few reports have documented various forms of glomerulonephritis in patients with MDS and suggested that immune dysregulation is important in the development of paraneoplastic glomerulonephritis. Here, we report a patient with MDS and refractory anemia with excess blast-2 accompanied by minimal change nephrotic syndrome. The patient was treated with prednisolone, and the nephrotic-range proteinuria and pancytopenia improved markedly.
